Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial Cells

Circulation

Volumn 128, Issue 23, 2013, Pages 2504-2516

  Jane Wit, Dan ^a   Manes, Thomas D ^b   Yi, Tai ^b   Qin, Lingfeng ^b   Clark, Pamela ^b   Kirkiles Smith, Nancy C ^b   Abrahimi, Parwiz ^b   Devalliere, Julie ^b   Moeckel, Gilbert ^c   Kulkarni, Sanjay ^b   Tellides, George ^b   Pober, Jordan S ^b,c  

^a Section of Cardiovascular Medicine   (United States)

^b Department of Immunobiology ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arteriosclerosis; endothelium; transplantation

Indexed keywords

ALLOANTIBODY; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PANEL REACTIVE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CORONARY ARTERY; CYTOLYSIS; ENDOTHELIUM CELL; GENE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY BIOPSY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETRANSPLANTATION; T CELL MEDIATED CARDIAC ALLOGRAFT VASCULOPATHY; T LYMPHOCYTE; XENOGRAFT;

ARTERIOSCLEROSIS; ENDOTHELIUM; TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; CORONARY VESSELS; ENDOTHELIAL CELLS; FEMALE; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOANTIBODIES; MICE; MICE, SCID; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84889089305     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002972     Document Type: Article

References (36)

1. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant. 2009;28:1007-1022.
2. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, Starling RC, Uber PA. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-727.
3. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant. 2011;30:612-617.
4. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798.
5. Atkinson C, Horsley J, Rhind-Tutt S, Charman S, Phillpotts CJ, Wallwork J, Goddard MJ. Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. J Heart Lung Transplant. 2004;23:427-435.
6. Normann SJ, Khan SR, Leelachaikul P, Salomon DR. Origin of cells in the coronary intima during acute vascular rejection of the transplanted human heart. J Heart Lung Transplant. 1992;11(3 Pt 1):492-499.
7. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801-815.
8. Van Hoffen E, Gmelig-Meyling FH, Bosboom-Kalsbeek KC, Hu H, De Jonge N, Tilanus MG, Lahpor JR, De Weger RA. Cytokine messenger RNA expression by donor-specific cytotoxic T-cell clones after allogeneic heart transplantation. J Heart Lung Transplant. 1997;16: 216-221.
9. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. 2000;403:207-211.
10. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560-569.
11. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiff JM, Carr EJ, Pober JS. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol. 2007;179: 4397-4404.
12. Tellides G, Pober JS. Interferon-gamma axis in graft arteriosclerosis. Circ Res. 2007;100:622-632.
13. Petrossian GA, Nichols AB, Marboe CC, Sciacca R, Rose EA, Smith CR, Cannon PJ, Reemtsma K, Powers ER. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation. 1989;80(pt 2): III122-III125.
14. Suciu-Foca N, Reed E, Marboe C, Harris P, Yu PX, Sun YK, Ho E, Rose E, Reemtsma K, King DW. The role of anti-HLA antibodies in heart transplantation. Transplantation. 1991;51:716-724.
15. Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant. 1992;11(pt 1):24-29.
16. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant. 2008;8:1367-1373.
17. Racusen LC, Regele H. The pathology of chronic allograft dysfunction. Kidney Int Suppl. 2010;119:S27-S32.
18. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10:26-29.
19. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32:98-105.
20. Mannam VK, Lewis RE, Cruse JM. The fate of renal allografts hinges on responses of the microvascular endothelium. Exp Mol Pathol. 2013;94:398-411.
21. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809-3814.
22. Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z. Cell signals transduced by complement. Mol Immunol. 2004;41:583-597.
23. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and plateletderived growth factor from endothelial cells. J Exp Med. 1994;179: 985-992.
24. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol. 1996;149:953-961.
25. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factorkappa B activation. Am J Pathol. 1997;150:2019-2031.
26. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation. 2005;79(suppl):S19-S21.
27. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, Wasowska BA, Baldwin WM III, Pober JS, Lowenstein CJ. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA. 2007;104:1301-1306.
28. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol. 1996;168:625-637.
29. Galvani S, Augé N, Calise D, Thiers JC, Canivet C, Kamar N, Rostaing L, Abbal M, Sallusto F, Salvayre R, Böhler T, Zou Y, Stastny P, Nègre-Salvayre A, Thomsen M. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant. 2009;9:2607-2614.
30. Hirohashi T, Uehara S, Chase CM, DellaPelle P, Madsen JC, Russell PS, Colvin RB. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant. 2010;10: 510-517.
31. Lee CY, Lotfi-Emran S, Erdinc M, Murata K, Velidedeoglu E, Fox-Talbot K, Liu J, Garyu J, Baldwin WM III, Wasowska BA. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation. 2007;84:1324-1334.
32. Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012;12:313-321.
33. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8:582-587.
34. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28:425-435.
35. Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant. 2009;9:1784-1795.
36. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-?B signaling pathways. Nat Immunol. 2011;12:695-708.